| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a Division of Radiation Oncology, Department of Clinical Oncology, Marshfield Clinic Cancer Center, Marshfield, Wisconsin and The Meta-Analysis Research Group, Stevens Point, Wisconsin, USA; b Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Correspondence: Michael Huncharek, M.D., M.P.H., F.A.C.A., Meta-Analysis Research Group, 2740 Sunset Boulevard, Stevens Point, Wisconsin 54481, USA. Telephone: 715-343-3035; Fax: 715-343-3080; e-mail: Huncharek.Michael{at}Marshfieldclinic.org
The objective of this study was to determine whether initial combined chemoradiation results in superior 1-, 2-, and 3-year survivals in the treatment of limited-stage small cell lung cancer versus sequential or split-course therapy. Using a prospective meta-analysis protocol outlining study inclusion criteria, literature search strategy, and statistical procedures, data from all available randomized controlled trials addressing the above-noted objective were pooled using a fixed effects model (Peto). Results were expressed as summary odds ratios (ORp), and statistical tests for data heterogeneity were performed prior to calculation of ORps. Odds ratios greater than 1.0 favored the experimental arm versus control (i.e., early chest irradiation). If statistical heterogeneity was demonstrated, sensitivity analyses were performed by previously described methods to evaluate possible sources of heterogeneity across the included studies. Pooling data from eight randomized controlled trials enrolling over 1,500 patients showed that early integration of chest radiotherapy with systemic chemotherapy increases overall survival by 34%–216%, depending on the end point of interest. Etoposide (E) plus cisplatin (P) in conjunction with chest irradiation appears to offer the greatest increase in survival versus delayed or split-course radiation therapy and non-EP-containing drug schedules. The available randomized trial data support early concurrent chest radiotherapy and systemic chemotherapy in the form of E and P in the management of limited-stage small cell lung cancer.
This article has been cited by other articles:
 |
|
 |
|
  J. P. Sculier, J. J. Lafitte, A. Efremidis, M. C. Florin, J. Lecomte, M. C. Berchier, M. Richez, T. Berghmans, A. Scherpereel, A. P. Meert, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer Ann. Onc., October 1, 2008; 19(10): 1691 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Busse, J. R. Clark, V. V. Muse, and V. Liu Case 19-2008 -- A 63-Year-Old HIV-Positive Man with Cutaneous Merkel-Cell Carcinoma N. Engl. J. Med., June 19, 2008; 358(25): 2717 - 2723. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski and J. A. Bogart Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rossi, P. Maione, G. Colantuoni, C. Guerriero, C. Ferrara, F. Del Gaizo, D. Nicolella, and C. Gridelli Treatment of Small Cell Lung Cancer in the Elderly Oncologist, June 1, 2005; 10(6): 399 - 411. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
